The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) is a huge mover today! About 5.86 million shares traded hands or 236.78% up from the average. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has declined 36.25% since April 5, 2016 and is downtrending. It has underperformed by 38.21% the S&P500.
The move comes after 8 months positive chart setup for the $3.81B company. It was reported on Nov, 7 by Barchart.com. We have $41.14 PT which if reached, will make NASDAQ:IONS worth $1.10B more.
Analysts await Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report earnings on November, 14. They expect $-0.01 earnings per share, up 96.67% or $0.29 from last year’s $-0.3 per share. After $-0.47 actual earnings per share reported by Ionis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -97.87% EPS growth.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Ratings Coverage
Out of 2 analysts covering Ionis Pharmaceuticals Inc (NASDAQ:IONS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Ionis Pharmaceuticals Inc has been the topic of 3 analyst reports since February 22, 2016 according to StockzIntelligence Inc. The firm has “Market Perform” rating given on Friday, May 27 by BMO Capital Markets. The rating was maintained by Needham on Friday, May 27 with “Buy”.
According to Zacks Investment Research, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.”
More notable recent Ionis Pharmaceuticals Inc (NASDAQ:IONS) news were published by: Schaeffersresearch.com which released: “Buzz Stocks: Cempra Inc, Ionis Pharmaceuticals Inc, and LendingClub Corp” on November 07, 2016, also Fool.com with their article: “Better Buy: Ionis Pharmaceuticals, Inc. vs. Celgene” published on October 17, 2016, Prnewswire.com published: “Webcast Alert: Ionis Pharmaceuticals’ Third Quarter 2016 Financial Results …” on October 26, 2016. More interesting news about Ionis Pharmaceuticals Inc (NASDAQ:IONS) were released by: Fool.com and their article: “5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now” published on October 28, 2016 as well as Fool.com‘s news article titled: “Is AveXis a Major Threat to Ionis Pharmaceuticals?” with publication date: October 14, 2016.
IONS Company Profile
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., incorporated on March 25, 1991, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Firm operates through two divisions: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the activities of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Firm is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. The Company’s Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.